Sugi Predict

Sugi Predict / Compounds / SCHEMBL4309526

SCHEMBL4309526

SCHEMBL4309526

NC(=O)c1ccnc(N2CCCC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKD1 Q15139 3/20 0.60
▸ PRKD2 Q9BZL6 3/20 0.60
▸ PRKD3 O94806 1/20 0.60
▸ PIK3CA P42336 2/20 0.55
▸ PROKR1 Q8TCW9 4/20 0.51
▸ CTSA P10619 1/20 0.46
▸ HRH4 Q9H3N8 1/20 0.45
▸ HDAC3 O15379 2/20 0.45
▸ HDAC1 Q13547 2/20 0.45
▸ PRMT5 O14744 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM4B O94953 1/20 0.44
▸ KDM5C P41229 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ UBE2T Q9NPD8 1/20 0.44
▸ AURKA O14965 1/20 0.43
▸ RPS6KB1 P23443 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30290310 0.98 PRKD3 (0.62) PRKD1PRKD2PRKD3PIK3CAPROKR1
SCHEMBL27991055 0.86 PIK3CA (0.58) PRKD1PRKD2PRKD3PIK3CAPROKR1
SCHEMBL29889392 0.86 PIK3CA (0.76) PRKD1PRKD2PRKD3PIK3CAPRMT5
SCHEMBL7887377 0.86 KDM4E (0.55) PRKD1PRKD2PRKD3PIK3CAHRH4
SCHEMBL27786169 0.86 PRKD1 (0.66) PRKD1PRKD2PRKD3PIK3CAKDM5C
SCHEMBL3554847 0.86 PIK3CA (0.76) PRKD1PRKD2PRKD3PIK3CAPRMT5
SCHEMBL1516867 0.85 PIK3CA (0.74) PRKD1PRKD2PRKD3PIK3CAPROKR1
SCHEMBL31143236 0.85 PIK3CA (0.74) PRKD1PRKD2PRKD3PIK3CAPROKR1
SCHEMBL1255519 0.83 PIK3CA (0.72) PRKD1PRKD2PRKD3PIK3CAPROKR1
SCHEMBL30505327 0.83 PIK3CA (0.72) PRKD1PRKD2PRKD3PIK3CAPROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 — — EP claimed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 — — WO claimed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-20180148440-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-05-31 — — US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 — — US disclosed
EP-3174868-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS Nuevolution A/S (DK) 2017-06-07 — — EP disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-20170037042-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2017-02-09 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20130065859-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2013-03-14 — — US disclosed
EP-2567958-A1 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals SANOFI (FR) 2013-03-13 — — EP disclosed
WO-2009130015-A1 IMPROVED RAF INHIBITORS GPC BIOTECH AG (DE) 2009-10-29 — — WO disclosed
EP-1888579-A2 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF Aventis Pharma S.A. (FR) 2008-02-20 — — EP disclosed
WO-2006123061-A2 FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-23 — — WO disclosed
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 — — EP disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148440-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, P2RX1 PRKD1 4047/4885PRKD2 3989/4885PRKD3 2223/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK PRKD1 491/4885PRKD2 261/4885PRKD3 374/4885
US-20130065859-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, RYR1 PRKD1 3754/4885PRKD2 3795/4885PRKD3 1945/4885
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT PRKD1 806/4885PRKD2 436/4885PRKD3 313/4885
US-20170037042-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, P2RX1 PRKD1 4047/4885PRKD2 3989/4885PRKD3 2223/4885
US-10752640-B2 Compounds active towards bromodomains BRD4, BRD3, BRDT PRKD1 806/4885PRKD2 436/4885PRKD3 313/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PRKD1 518/4885PRKD2 308/4885PRKD3 405/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PRKD1 518/4885PRKD2 308/4885PRKD3 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.